This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Genmab A+s. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Pilar Martinez-Martinez: Innovator in Autoimmune Disease Treatment
Introduction
Pilar Martinez-Martinez is a distinguished inventor based in Maastricht, Netherlands. She has made significant contributions to the field of medicine, particularly in the treatment of autoimmune diseases. Her innovative approach focuses on the use of effector-function-deficient antibodies, which has the potential to transform therapeutic strategies for conditions like myasthenia gravis.
Latest Patents
Pilar holds a patent for her invention titled "Use of effector-function-deficient antibodies for treatment of auto-immune diseases." This patent addresses the treatment of autoimmune diseases and disorders by administering antibodies that can compete with auto-antibodies for binding to target auto-antigens. This innovative method aims to improve patient outcomes in autoimmune conditions.
Career Highlights
Pilar is currently associated with Genmab A/S, a leading biotechnology company specializing in the development of innovative antibody therapeutics. Her work at Genmab has positioned her as a key player in the advancement of treatments for autoimmune diseases. With her expertise, she has contributed to the company's mission of improving patient lives through groundbreaking therapies.
Collaborations
Pilar collaborates with notable colleagues, including Marc H De Baets and Yvo Graus. These partnerships enhance her research and development efforts, fostering an environment of innovation and shared knowledge in the field of autoimmune disease treatment.
Conclusion
Pilar Martinez-Martinez is a pioneering inventor whose work in autoimmune disease treatment exemplifies the impact of innovative research in medicine. Her contributions through patents and collaborations continue to pave the way for advancements in therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
